Eylea® Intravitreal Injection for Retinal Vascular Conditions

What Eylea® Is and How It Works

Eylea® (aflibercept) is a VEGF inhibitor given by intravitreal injection. It treats wet age‑related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and myopic choroidal neovascularization. The typical eylea dose is 2 mg per injection, administered by a retina specialist at set intervals. For budgeting, some patients compare options for eylea without insurance. CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies. We supply authentic brand medications through vetted partners, with a broad selection and value‑focused pricing.

Aflibercept binds vascular endothelial growth factor‑A (VEGF‑A), VEGF‑B, and placental growth factor. By neutralizing these growth factors, it reduces abnormal vessel leakage and growth in the retina and choroid. Reduced fluid can improve or stabilize vision and decrease retinal thickening on OCT imaging.

Eylea is available as a single‑use vial or prefilled syringe in many markets. Treatment schedules vary by diagnosis and response. Some patients remain on fixed intervals, and others shift to a treat‑and‑extend approach to balance disease control and visit burden.

Common conditions include Age Related Macular Degeneration and Diabetic Macular Edema. Your clinic determines the exact plan based on exam findings, OCT, and visual function.

Dosage and Usage

• Wet AMD: 2 mg every 4 weeks for the first 3 doses, then every 8 weeks. Some patients can extend beyond 8 weeks if disease remains controlled.
• Diabetic Macular Edema: 2 mg every 4 weeks for 5 doses, then every 8 weeks. Many clinics individualize further using a treat‑and‑extend strategy.
• Diabetic Retinopathy (with or without DME): Often 2 mg every 4 weeks initially, then every 8 weeks. Interval adjustments depend on regression of retinopathy and macular status.
• Retinal Vein Occlusion (CRVO/BRVO): 2 mg every 4 weeks until vision and anatomy stabilize. Some patients can extend intervals once stable.
• Myopic CNV: Typically a single 2 mg injection, with additional doses if activity returns.
• Eylea 8 mg (high‑dose): In markets where approved, 8 mg may be given monthly for 3 doses, then every 8–16 weeks for wet AMD or DME. Availability can vary by region and product.
• Missed appointment: Contact the clinic to reschedule as soon as possible to maintain disease control.
• Administration: An ophthalmologist injects the medicine into the vitreous under sterile conditions after anesthetic and antiseptic prep.
• What to expect: Brief pressure or mild discomfort can occur. Post‑injection checks often include intraocular pressure measurement and infection precautions.

• Storage (if your clinic asks you to bring the product): Keep refrigerated at 2–8°C (36–46°F) in the original carton; protect from light.
• Do not freeze. Do not shake. Do not use if the solution is cloudy, discolored, or contains particles.
• Allow to reach room temperature naturally before the visit (follow clinic guidance). Do not heat.
• Travel: Use an insulated cooler with frozen gel packs and a buffer (e.g., a cloth). Avoid direct contact between the syringe or vial and ice packs to prevent freezing.
• Keep upright in its carton during transport. Minimize time out of refrigeration per pharmacy instructions.
• Shipping: Orders are packed with cold protection to maintain the cold chain.

Benefits and Savings

Eylea can reduce retinal fluid, stabilize the macula, and improve vision in many patients. Strong clinical data support its use across wet AMD, DME, DR, and RVO. Clinic‑guided extensions can reduce injection frequency while maintaining control in responsive cases. Prefilled syringes (where available) add convenience and help standardize dosing.

Many customers save 60–80% vs typical U.S. prices. Savings may help offset costs for patients paying cash, including those seeking Eylea without insurance through a licensed Canadian source. See our eylea discount and other offers on the promotions page if available.

Side Effects and Safety

• Transient eye pain, irritation, or a sensation of fullness
• Conjunctival hemorrhage (small red patch on the white of the eye)
• Floaters or visual spots after injection
• Temporary blurred vision
• Increased intraocular pressure shortly after injection
• Mild eyelid swelling or tearing

Serious but less common risks include endophthalmitis (eye infection), retinal detachment, intraocular inflammation, cataract from lens injury, and arterial thromboembolic events. Eylea is contraindicated with active ocular or periocular infection, active intraocular inflammation, or known hypersensitivity to aflibercept. Use caution in pregnancy and discuss timing and contraception with the treating clinician.

Onset Time

Fluid reduction on OCT can appear within days to weeks after the first injection. Many patients notice vision stabilization or gains over 4–12 weeks as loading doses are completed. Ongoing control is maintained with regular dosing. If intervals are extended, the clinic monitors closely for any recurrence and adjusts timing.

Compare With Alternatives

Other anti‑VEGF options include ranibizumab (Lucentis) and brolucizumab (Beovu). Lucentis has longstanding evidence in wet AMD, DME, and RVO, with flexible interval strategies. Beovu allows longer intervals in some cases, with specific monitoring needs for intraocular inflammation and occlusive vasculitis.

Explore alternatives we carry: Beovu Pre Filled Syringe and Product Lucentis Prefilled Syringe. For a head‑to‑head overview, see our article Eylea Vs Lucentis for clinical context.

In some DME cases, intravitreal corticosteroids (e.g., triamcinolone) are considered, especially in pseudophakic eyes or when anti‑VEGF response is limited. These choices depend on individual risk profiles and cataract or IOP considerations.

Combination Therapy

• Panretinal photocoagulation for proliferative diabetic retinopathy, alongside anti‑VEGF to control neovascularization.
• Focal/grid laser in select DME cases after edema is better controlled.
• Intravitreal steroid options (such as triamcinolone) for refractory DME, with careful IOP and cataract monitoring.
• Treat‑and‑extend protocols to gradually lengthen intervals while maintaining anatomic dryness.
• Avoid concurrent use of multiple anti‑VEGF agents in the same eye.

Patient Suitability and Cost‑Saving Tips

Candidates often include adults with active neovascular AMD, center‑involving DME, vision‑threatening DR, macular edema from RVO, or myopic CNV. Those with active eye infection, intraocular inflammation, or a history of serious hypersensitivity to aflibercept should not receive injections. Caution may be needed for recent stroke or uncontrolled glaucoma, guided by specialist judgment.

Cost‑saving tips: discuss multi‑month ordering to reduce per‑shipment fees, coordinate clinic calendars to limit urgent resends, and set gentle reminders so refills arrive before scheduled visits. CanadianInsulin offers value‑focused pricing and prompt support, and ships under cold conditions to protect product integrity.

Authoritative Sources

Regeneron Eylea product page (mechanism, indications, PI) | FDA Drugs@FDA listing for Eylea (aflibercept) | Bayer overview of aflibercept ophthalmology use

Order Eylea® from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold‑chain handling.

This page is for educational purposes only and does not replace advice from your eye care professional. Always follow your clinic’s guidance on diagnosis, dosing, and follow‑up.